Posts by Peter W. PENG

For patients with non-muscle invasive bladder cancer (NMIBC), transurethral resection of bladder tumor (TURBt) and intravesical instillation remain the mainstays of treatment. However, a subset of high- or very high-risk…

The 19th St. Gallen Breast Cancer Conference (SGBCC), held in Vienna from March 12 to 15, 2025, remains one of the most influential global platforms in early breast cancer care. Among seven studies awarded the prestigious Best Poster Award, four came from China, including a multi-center real-world study led by Professor Ying Fan from the Cancer Hospital Chinese Academy of Medical Sciences. Her research focused on treatment-insensitive HER2-positive breast cancer patients undergoing neoadjuvant therapy. Oncology Frontier spoke with Professor Fan to learn more about the study’s results, and broader implications.

Prostate cancer remains one of the most prevalent malignancies threatening men’s health worldwide. A major research focus today lies in developing accurate screening and diagnostic strategies that minimize the invasiveness and psychological burden of biopsy procedures. Landmark studies like SMART and PRECISION aim to address these challenges. At the 2025 European Association of Urology (EAU) Annual meeting, Professor Chiu Ka Fung Peter from the Department of Urology at The Chinese University of Hong Kong presented the latest findings from the SMART study. Following his presentation, Professor Chiu spoke with UroStream to share key updates in prostate cancer diagnostics and care.

Breast cancer remains one of the leading malignancies threatening women’s health worldwide. Among its various subtypes, hormone receptor-positive (HR⁺) breast cancer is the most prevalent, comprising about 70% of all cases. While the advent of CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) has become the gold standard for first-line treatment of HR⁺/HER2⁻ advanced breast cancer (MBC), therapeutic strategies following progression on CDK4/6i remain a considerable challenge. The introduction of the histone deacetylase inhibitor (HDACi) entinostat has brought a new horizon of hope for patients in this therapeutic gap. Recently, entinostat prescriptions were issued across major cities in China, such as Beijing and Guangdong, marking a pivotal moment in the treatment landscape. Oncology Frontier invited Dr. Xiaojia Wang from Zhejiang Cancer Hospital to delve deeper into the current status of HR⁺/HER2⁻ MBC treatment, strategies after CDK4/6i failure, and the efficacy and safety profile of entinostat.

Breast cancer remains one of the most prevalent malignancies among women worldwide, and its hormone receptor-positive, HER2-negative (HR+/HER2−) subtype accounts for nearly 70% of all cases. In recent years, the combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has become the gold standard for first-line treatment in metastatic settings. However, once progression occurs on CDK4/6i-based regimens, the optimal path forward is less clearly defined, presenting a persistent challenge in clinical decision-making.

PARP inhibitors (PARPi) have ushered in a new era of precision treatment for prostate cancer. Multiple studies have confirmed that patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair deficiency mutations (HRRm) can benefit from this therapeutic approach. At the recently held 2025 European Association of Urology(EAU25) conference , a single-arm Phase II PROact study conducted by Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University, was reported. The study demonstrated promising preliminary efficacy and safety of the combination of olaparib, abiraterone, and prednisone in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). UroStream was honored to invite Prof. Junlong Zhuang from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, and Prof. Samson Chan from Department of Surgery, Tuen Mun Hospital, HONG KONG, to engage in a dialogue and share the latest advancements and clinical experiences in precision therapy for prostate cancer.